Advanced search
Publication Cover
Neuropsychiatric Disease and Treatment Volume 15, 2019 - Issue
Submit an article Journal homepage
65
Views
2
CrossRef citations to date
0
Altmetric
Original Research

The Relationship Between Course of Illness and β-Endorphin Plasma Levels in Patients with Schizophrenia

Małgorzata Urban-Kowalczyk1 Department of Affective and Psychotic Disorders, Medical University of Łódź, Łódź, PolandCorrespondence[email protected]
,
Magdalena Kotlicka-Antczak1 Department of Affective and Psychotic Disorders, Medical University of Łódź, Łódź, Poland
,
Dominik Strzelecki1 Department of Affective and Psychotic Disorders, Medical University of Łódź, Łódź, PolandORCID Iconhttps://orcid.org/0000-0002-8559-1078
ORCID Icon,
Ewa Rudecka2 Babiński Memorial Hospital in Łódź, Łódź, Poland;3 Faculty of Human Nutrition and Consumer Sciences, Warsaw University of Life Sciences SGGW, Warsaw, Poland
&
Janusz Śmigielski4 State High Vocational School in Konin, Konin, Poland
Pages 3609-3614 | Published online: 03 Jan 2020

References

  • Rapoport JL, Giedd JN, Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Mol Psychiatry. 2012;17:1228–1238. doi:10.1038/mp.2012.2322488257
  • Möller H-J, Jäger M, Riedel M, Obermeier M, Strauss A, Bottlender R. The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: comparison of psychopathological and psychosocial course and outcome and prediction of chronicity. Eur Arch Psychiatry Clin Neurosci. 2010;260:367–384. doi:10.1007/s00406-010-0117-y20495979
  • Harrison G, Hopper K, Craig T, et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry. 2001;178:506–517. doi:10.1192/bjp.178.6.50611388966
  • Volavka J, Davis LG, Ehrlich YH. Endorphins, dopamine, and schizophrenia. Schizophr Bull. 1979;5(2):227–239. doi:10.1093/schbul/5.2.22737595
  • Fricchione GL, Mendoza A, Stefano GB. Morphine and its psychiatric implications. Adv Neuroimmunol. 1994;4(2):117–131. doi:10.1016/S0960-5428(05)80006-37952828
  • Mauri MC, Rudelli R, Vanni S, et al. Cholecystokinin, beta-endorphin and vasoactive intestinal peptide in peripheral blood mononuclear cells of drug-naive schizophrenic patients treated with haloperidol compared to healthy controls. Psychiatry Res. 1998;20(1–2):45–50. doi:10.1016/S0165-1781(97)00145-5
  • Panza G, Monzani E, Sacerdote P, Penati G, Panerai AE. Beta-endorphin, vasoactive intestinal peptide and cholecystokinin in peripheral blood mononuclear cells from healthy subjects and from drug-free and haloperidol treated schizophrenic patients. Acta Psychiatr Scand. 1992;85:207–210. doi:10.1111/acp.1992.85.issue-31561892
  • Rapaport MH, Wolkowitz O, Kelsoe JR, Pato C, Konicki PE, Pickar D. Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients. Neuropsychopharmacology. 1993;9(2):111–115. doi:10.1038/npp.1993.498105790
  • Urban-Kowalczyk M, Śmigielski J, Strzelecki D. Comparison of beta-endorphin and CGRP levels before and after treatment for severe schizophrenia. Neuropsychiatr Dis Treat. 2016;12:863–868. doi:10.2147/NDT.S10164727143887
  • Urban-Kowalczyk M, Śmigielski J, Kotlicka-Antczak M. Overrated hedonic judgment of odors in patients with schizophrenia. CNS Neurosci Ther. 2018;24(12):1156–1162. doi:10.1111/cns.1284929638031
  • Millan MJ, Fone K, Steckler T, Horan WP. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014;24:645–692. doi:10.1016/j.euroneuro.2014.03.00824820238
  • Schultze-Lutter F, Michel C, Schmidt SJ, et al. EPA guidance on the early detection of clinical high risk states of psychoses. Eur Psychiatry. 2015;30:405–416. doi:10.1016/j.eurpsy.2015.01.01025735810
  • Brousse G, Meary A, Blanc O, Lancon C, Llorca PM, Leboyer M. Clinical predictors of response to olanzapine or risperidone during acute episode of schizophrenia. Psychiatry Res. 2010;179(1):12–18. doi:10.1016/j.psychres.2009.03.00320472305
  • Chanpattana W, Sackeim HA. Electroconvulsive therapy in treatment-resistant schizophrenia: prediction of response and the nature of symptomatic improvement. J ECT. 2010;26(4):289–298. doi:10.1097/YCT.0b013e3181cb5e0f20375701
  • Brambilla F, Facchinetti F, Petraglia F, Vanzulli L, Genazzani AR. Secretion pattern of endogenous opioids in chronic schizophrenia. Am J Psychiatry. 1984;141(10):1183–1189.6091463
  • Brambilla F, Facchinetti F, Petraglia F, et al. Effects of neuroleptic treatments on peripheral opioid secretion. Neuropsychobiology. 1987;18(2):68–73. doi:10.1159/0001183952897644
  • Urban-Kowalczyk M, Strzelecki D, Śmigielski J, Kotlicka-Antczak M. Odor perception and hedonics in chronic schizophrenia and in first episode psychosis. Neuropsychiatr Dis Treat. 2019;15:647–654. doi:10.2147/NDT.S19252330880989
  • Hӓfner H, Maurer K, van der Heiden W. ABC Schizophrenia study: an overview of results since 1996. Soc Psychiatry Psychiatr Epidemiol. 2013;48(7):1021–1031. doi:10.1007/s00127-013-0700-423644725
  • Schultz SK, Miller Del D, Oliver SE, Arndt S, Flaum M, Andreasen NC. The life course of schizophrenia: age and symptom dimensions. Schizophrenia Res. 1997;23(1):15–23. doi:10.1016/S0920-9964(96)00087-4
  • Hӓfner H. What is schizophrenia? 25 years of research into schizophrenia - the Age Beginning Course Study. World J Psychiatry. 2015;5(2):167–169. doi:10.5498/wjp.v5.i2.16726110118
  • Hӓfner H. From onset and prodromal stage to a life-long course of schizophrenia and its symptom dimensions: how sex, age, and other risk factors influence incidence and course of illness. Psychiatry J. 2019;2019:1–15. doi:10.1155/2019/9804836

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.